使用骨-髌腱-骨移植物联合改良Lemaire技术对比腘绳肌腱移植物联合前外侧韧带重建翻修前交叉韧带重建:来自SANTI研究组的平均5年随访临床对比匹配研究
本研究比较翻修前交叉韧带重建中采用腘绳肌腱联合前外侧韧带重建(HT-ALL)与骨-髌腱-骨联合改良Lemaire腱固定(BPTB-Lemaire)的临床结局。共匹配36对患者,平均随访约5年,两组在移植物断裂率、再手术率、膝关节松弛度、重返运动和临床评分上无显著差异,仅Tegner活动量表评分BPTB-Lemaire组更高,HT-ALL组手术时间更短。结论认为HT-ALL在临床结局上不劣于BPTB-Lemaire,在翻修ACLR中行ALL重建安全有效。
要点
- 翻修ACLR中HT-ALL与BPTB-Lemaire两组移植物断裂率和再手术率无显著差异。
- 两组膝关节松弛度、重返运动和多数临床评分无显著差异,仅Tegner评分BPTB-Lemaire组更高。
- HT-ALL组手术时间显著短于BPTB-Lemaire组。
核心结论
- HT-ALL在临床结局上至少不劣于更常进行的BPTB-Lemaire术式。
- 在翻修ACLR中行ALL重建因此是安全有效的。
研究设计与样本
- 队列研究,证据等级3。
- 前瞻性收集2009年至2018年间接受翻修ACLR联合LET且至少随访2年的患者的描述性数据和临床结局。
- 将HT自体移植物联合ALL重建(HT-ALL组)的患者按1:1倾向性评分匹配至BPTB自体移植物联合改良Lemaire LET(BPTB-Lemaire组)的患者。
- 共纳入36对匹配患者;BPTB-Lemaire组和HT-ALL组平均随访时间分别为56±35个月和57±23个月(P=0.91)。
主要发现
- 移植物断裂率:HT-ALL组0% vs BPTB-Lemaire组11.1%(P=0.13),无显著差异。
- 再手术率:HT-ALL组8.3% vs BPTB-Lemaire组22.2%(P=0.23),无显著差异。
- 两组均未注意到与LET相关的特定并发症。
- 末次随访时,除Tegner活动量表评分(HT-ALL组6.4 vs BPTB-Lemaire组7.3,P=0.03)外,两组膝关节松弛度参数、重返运动和临床评分均无显著差异。
- HT-ALL组手术时间更短(41.4 vs 59.8分钟;P<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Additional lateral extra-articular tenodesis (LET) has recently been correlated with improved clinical outcomes and reduced failure rates in revision anterior cruciate ligament (ACL) reconstruction (ACLR). However, no data are available on clinical outcomes and reoperation after revision ACLR using different LET procedures. PURPOSE: To compare the clinical outcomes of ACL + anterolateral ligament (ALL) reconstruction using hamstring tendon graft (HT-ALL) and a bone-patellar tendon-bone (BPTB) graft + modified Lemaire tenodesis procedure (BPTB-Lemaire) in the setting of revision ACLR and to determine whether ALL reconstruction is associated with an increased rate of adverse outcomes when compared with a modified Lemaire tenodesis procedure. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: Descriptive data and clinical outcomes were prospectively collected from patients who underwent revision ACLR with LET between 2009 and 2018 with a minimum follow-up of 2 years. Patients with an HT autograft combined with ALL reconstruction (HT-ALL group) were matched in a 1:1 propensity ratio to patients with a BPTB autograft combined with a modified Lemaire LET procedure (BPTB-Lemaire group). The evaluated parameters included complications and reoperations; knee laxity tests; return to sports; and various scores, including the Lysholm knee score, Tegner activity scale, Anterior Cruciate Ligament Return to Sport After Injury scale, Marx activity rating scale, International Knee Documentation Committee subjective knee evaluation form, and Knee injury and Osteoarthritis Outcome Score. RESULTS: In total, 36 matched pairs were included in the analysis. The mean follow-up durations for the BPTB-Lemaire and HT-ALL groups were 56 ± 35 and 57 ± 23 months, respectively (P = .91). No significant differences were found in graft rupture rate (HT-ALL, 0%; BPTB-Lemaire, 11.1%; P = .13) or reoperations (HT-ALL, 8.3%; BPTB-Lemaire, 22.2%; P = .23). No specific complications with regard to LET were noted in either group. Additionally, there were no significant differences in knee laxity parameters, return to sports, or clinical scores between the groups at the final follow-up, except for the Tegner activity scale score (HT-ALL, 6.4; BPTB-Lemaire, 7.3; P = .03). HT-ALL was associated with a shorter surgical time (41.4 vs 59.8 minutes; P < .0001). CONCLUSION: HT-ALL was at least equivalent, in terms of clinical outcomes, to the more commonly performed procedure, BPTB-Lemaire. Performing ALL reconstruction in the setting of revision ACLR is therefore safe and effective.
引用
- Rayes J, Ouanezar H, Haidar IM, et al. Revision Anterior Cruciate Ligament Reconstruction Using Bone-Patellar Tendon-Bone Graft Combined With Modified Lemaire Technique Versus Hamstring Graft Combined With Anterolateral Ligament Reconstruction: A Clinical Comparative Matched Study With a Mean Follow-up of 5 Years From The SANTI Study Group. Am J Sports Med. 2021. PMID: 34898285. doi:10.1177/03635465211061123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。